根据名称进行药物检索

Rifater 与 Sandimmune (Cyclosporine Oral Solution)

Rifater 与 Sandimmune (Cyclosporine Oral Solution)互相作用以及同时服用的可能性。

检测结果:

Rifater <> Sandimmune (Cyclosporine Oral Solution)

现实性: 22.05.2023 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

使用孢菌素和种药物在一起，可以使环孢霉素不那么有效。鉴于风险的机构拒绝与低cycloSPORINE的水平，谨慎建议，如果cycloSPORINE必须采取有利福平。你可能需要的剂量调整或特别的测试，如果你采取这两种药物。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

密切监测：共同给予有利福霉素类，特别是利福平，可以降低血液中的浓度和药物影响的环孢菌素。该机制可能涉及减少吸收，以及为加速清关的药由于感应两者的肠P-糖蛋白药物流出泵和肝/肠CYP450 3A4同功通过利福霉素类. 在一项研究的六个健康的志愿者，利福平(600毫克经口头在睡觉时间为11天)增加平均的血清的药(10毫克/千克的口头和3毫克/公斤静脉)通过40%，并降低其经口生物利用率从27％至10％。也有的情况报告的移植病人的药血液水平显着下降，往往低于测定法检测的限制，早在两天后开始的利福平。减少是与急性排斥在许多情况下，随后要求停止或利福平的大幅度增加药剂量。这种相互作用有可能发生与其他利福霉素类，但程度较轻。在体外和体内的酶的研究已经建议利福喷丁感应的潜力可比利福平，但比利福布丁.

管理：鉴于风险的机构拒绝与不充分的免疫抑制剂的水平，谨慎建议，如果孢菌素必须加服与利福霉素类，特别是利福平。 Cyclosporine的血液水平应密切监测和剂量进行相应的调整，特别是以下启动或中止的福霉素治疗的患者中稳定在他们抗拒绝的方案。

来源

"Product Information. Sandimmune (cyclosporine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Al-Sulaiman MH, Dhar JM, Al-Khader AA "Successful use of rifampicin in the treatment of tuberculosis in renal transplant patients immunosuppressed with cyclosporine." Transplantation 50 (1990): 597-8
Koselj M, Bren A, Kandus A, Kovac D "Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections." Transplant Proc 26 (1994): 2823-4
Van Buren D, Wideman CA, Ried M, et al. "The antagonistic effect of rifampin upon cyclosporin bioavailability." Transplant Proc 16 (1984): 1642-5
Modry DL, Stinson EB, Oyer PE, Jamieson SW, Baldwin JC, Shumway NE "Acute rejection and massive cyclosporin requirements in heart transplant recipients treated with rifampin." Transplantation 39 (1985): 313-4
Allen RD, Hunnisett AG, Morris PJ "Cyclosporin and rifampicin in renal transplantation." Lancet 1 (1985): 980
Offermann G, Keller F, Molzahn M "Low cyclosporine A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment." Am J Nephrol 5 (1985): 385-7
Yee GC, McGuire TR "Pharmacokinetic drug interactions with cyclosporin (Part I)." Clin Pharmacokinet 19 (1990): 319-32
Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ "Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction." Clin Pharmacol Ther 52 (1992): 453-7
Strayhorn VA, Baciewicz AM, Self TH "Update on rifampin drug interactions, III." Arch Intern Med 157 (1997): 2453-8
Daniels NJ, Dover JS, Schachter RK "Interaction between cyclosporin and rifampicin." Lancet 1 (1984): 639
Watkins PB "Drug metabolism by cytochromes P450 in the liver and small bowel." Gastroenterol Clin North Am 21 (1992): 511-26
Zylber-Katz E "Multiple drug interactions with cyclosporine in a heart transplant patient." Ann Pharmacother 29 (1995): 127-31
Langhoff E, Madsen S "Rapid metabolism of cyclosporin and prednisone in kidney transplant patient receiving tuberculostatic treatment." Lancet 2 (1983): 1031
Vandevelde C, Chang A, Andrews D, et al "Rifampin and ansamycin interaction with cyclosporine after renal transplantation." Pharmacotherapy 11 (1991): 88-9
Calne RY, White DJG, Thiru S, Rolles K, Drakopoulos S, Jamieson NV "Cyclosporin and antituberculous therapy." Lancet 1 (1985): 1342-3
Howard P, Bixler TJ, Gill B "Cyclosporine-rifampin drug interaction." Drug Intell Clin Pharm 19 (1985): 763-4
Cassidy MJ, Zyl-Smit RV, Pascoe MD, et al "Effect of rifampicin on cyclosporin A blood levels in a renal transplant recipient." Nephron 41 (1985): 207-8